AAS
EVFM

Avantax Advisory Services’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Avantax Advisory Services’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,181
Closed -$41K – 1395
2020
Q3 		$41K Buy
+1,181
New +$51.3K ﹤0.01% 1341

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return

Avantax Advisory Services's EVFM Position: Q4 2020 in Review

Avantax Advisory Services sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2020, closing a stake of 1,181 shares — an estimated $41K sold.

Avantax Advisory Services first reported a position in EVFM in Q3 2020 and held it in 1 quarter. The position peaked at $41K in Q3 2020. 93 funds tracked by Wall St. Rank hold EVFM as of Q4 2020.

  • Avantax Advisory Services reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Avantax Advisory Services sold 1,181 Evofem Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $41K.
  • Avantax Advisory Services first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Avantax Advisory Services's Evofem Biosciences, Inc. Common Stock position peaked at $41K in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2020.

Based on Avantax Advisory Services's 13F filing for Q4 2020, filed 22 Jan 2021.